Company
Headquarters: Birkerød, Denmark
Employees: 14
kr.39.1 Million
DKK as of Jan. 1, 2024
US$5.8 Million
Company | Market Cap (USD) |
---|---|
Abbott | $192.67 B |
Stryker Corporation | $113.24 B |
Medtronic | $111.60 B |
Boston Scientific Corporation | $85.22 B |
Shenzhen Mindray Bio-Medical Electronics Co. Ltd | $49.33 B |
Company | Market Cap (USD) |
---|---|
Lilly | $586.39 B |
UnitedHealth Group | $504.47 B |
Novo Nordisk | $461.52 B |
Johnson & Johnson | $387.50 B |
Merck | $296.51 B |
ViroGates A/S, a medical technology company, develops and markets prognostic products for the healthcare sector. It offers suPARnostic, a blood test that measures the suPAR (soluble urokinase plasminogen activator receptor) protein in the bloodstream used for emergency departments in hospitals to improve clinical decisions on hospitalization or discharge of acute medical patients and reduce healthcare cost. The company also provides suPARnostic TurbiLatex to help triage patients in the emergency setting and COVID-19 patients. In addition, its suPAR prognostic tool used in various diseases, such as cardiovascular, kidney, cancer, diabetes, liver, infectious, respiratory, and rheumatic. The company was founded in 2000 and is headquartered in Birkerød, Denmark. ViroGates A/S was formerly a subsidiary of Medicon Valley.
Top 1-year algo backtest: +313.24%
$10,000 in May 2023 would now be $41,324 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
ViroGates A/S has the following listings and related stock indices.
Stock: OMXC: VIRO wb_incandescent